(Q34093694)

31 July 2017

title

Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine (English)

1 reference

31 July 2017

1 reference

Ereshefsky L

1

1 reference

31 July 2017

Dugan D

series ordinal

2

1 reference

31 July 2017

language of work or name

1 reference

1 January 2000

1 reference

31 July 2017

published in

Depression and Anxiety

1 reference

31 July 2017

volume

12 Suppl 1

1 reference

31 July 2017

page(s)

30-44

1 reference

Patient-oriented strategies for the prevention of drug interactions

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Fluvoxamine-methadone interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Incidence and preventability of adverse drug events in hospitalized adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Pharmacoeconomics and therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Polymorphic cytochromes P450 and drugs used in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Drug-drug interactions involving antidepressants: focus on venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

The problems of anticholinergic adverse effects in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Clinical pharmacokinetics of nefazodone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Extrapyramidal symptoms after addition of fluvoxamine to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

The Nature of Adverse Events in Hospitalized Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Grapefruit juice substantially increases plasma concentrations of buspirone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Pharmacovigilance in perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Indinavir concentrations and St John's wort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

The pharmacokinetics of venlafaxine when given in a twice-daily regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Second thoughts about safety of St John's wort

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

Blockade of cardiac potassium and other channels by antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1520-6394%282000%2912%3A1%2B%3C30%3A%3AAID-DA4%3E3.0.CO%3B2-G

10.1002/1520-6394(2000)12:1+<30::AID-DA4>3.0.CO;2-G

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference